Immunotherapy and targeted drug before surgery for upper urinary tract cancer
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This study tests whether combining two drugs—toripalimab (an immunotherapy that boosts your immune system) and 9MW2821 (a targeted drug that delivers treatment directly to cancer cells)—before surgery helps shrink tumors and improves outcomes for people with upper tract urothelial cancer. The goal is to see if this combination is safe and effective before the kidney and ureter are removed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 80 years old.
- Your cancer must be in the renal pelvis or ureter (not the bladder) and have not spread to other parts of the body.
- You have not had chemotherapy, immunotherapy, or targeted therapy for this cancer before. (Bladder-only treatments may be okay.)
- You are eligible and willing to have surgery to remove the kidney and ureter.
- You have a tissue sample (biopsy) available for testing.
- You must be generally healthy, with no active infections or serious heart problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether combining the immunotherapy drug tislelizumab with the chemotherapy drug nab-paclitaxel before surgery can help treat high-risk upper tract urothelial cancer. The goal is to shrink the tumor and improve outcomes for patients who are planning to have their kidney and ureter removed.
This trial tests a combination of two drugs (disitamab vedotin and tislelizumab) to treat HER2-positive high-risk upper tract urothelial cancer, aiming to save the kidney instead of removing it. The drugs target cancer cells and boost the immune system to fight the cancer.
This trial tests a combination of two drugs and radiation therapy given before surgery for high-risk upper tract urothelial cancer. The goal is to see if this approach can improve outcomes for patients who are eligible for surgery.
This trial is testing a new combination of two drugs—9MW2821 (a targeted therapy) and toripalimab (an immunotherapy)—for people with advanced bladder cancer. It aims to see if using them together can help shrink tumors or slow the cancer's growth.
This trial is testing whether adding immunotherapy and radiation after surgery can improve outcomes for people with advanced upper tract urothelial cancer (UTUC) who cannot have chemotherapy. It compares the combination to surgery alone.
This trial compares combining immunotherapy with radiation versus standard chemotherapy for patients with high-risk upper urinary tract cancer after surgery. It aims to see if the new combination works better at preventing cancer from coming back.
Hear when a new Upper Tract Urothelial Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.